BBNX INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics

Core Viewpoint - Beta Bionics, Inc. has faced significant stock declines following disappointing preliminary fourth-quarter 2025 performance metrics, raising concerns among investors regarding the company's growth prospects [4][5]. Group 1: Company Performance - On January 9, 2026, Beta Bionics reported lower-than-expected new patient starts for its iLet automated insulin delivery system, which contributed to investor concerns about near-term adoption trends and revenue growth [5]. - Following the announcement, Beta Bionics' stock price dropped approximately $11.85, or 37.04%, closing at $20.14 on the same day [5]. Group 2: Legal Investigation - Faruqi & Faruqi, LLP is investigating potential claims against Beta Bionics for investors who suffered significant losses due to the stock's decline [2][4]. - The law firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [4].